Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Traws Reports Topline Results From Study Evaluating The Use Of Tivoxavir Marboxil As Treatment For Non-human Primates Challenged With Non-lethal Dose Of H5N1 Bird Flu; Results Build On Earlier Findings Of Mortality Benefit For TXM In Ferrets And Mice

Author: Benzinga Newsdesk | March 24, 2025 07:20am

TXM is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza.

Posted In: TRAW


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist